In situ depletion of CD4+ T cells in human skin by Zanolimumab

Archives of Dermatological Research

Volumn 298, Issue 9, 2007, Pages 449-455

  Villadsen, L S ^a   Skov, L ^a   Dam, T N ^b   Dagnaes Hansen F ^c   Rygaard, J ^d   Schuurman, J ^e   Parren, P W H I ^e   Van De Winkel, J G J ^e,f,g   Baadsgaard, O ^f  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e GENMAB   (Netherlands)

^f Genmab   (Denmark)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

CTCL; Human CD4 antibodies; Inflammatory skin diseases; Psoriasis; Xenograft model

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; PHOSPHATE BUFFERED SALINE; ZANOLIMUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DERMIS; DISEASE MODEL; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LYMPHOCYTE DEPLETION; MONONUCLEAR CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SKIN INFILTRATE; SKIN INFLAMMATION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MICE; MICE, SCID; PSORIASIS; SKIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 33846424911     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-006-0710-0     Document Type: Article

References (33)

1. Baadsgaard O, Tong P, Elder JT, Hansen ER et al (1990) UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol. 95:275-282
2. Bagel J, Garland T, Breneman D, Holick M et al (1998) Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 38:938-944
3. Baker BS, Swain AF, Valdimarsson H, Fry L (1984) T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol 110:37-44
4. Baker BS, Swain AF, Fry L, Valdimarsson H (1984) Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110:555-564
5. Chaudhari U, Romano P, Mulcahy LD, Dooley LT et al (2001) Efficacy and safety of Infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842-1847
6. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ (1999) 1α,25- dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 113:1082-1089
7. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248-255
8. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV et al (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat biotechnol 14:845-851
9. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L et al (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1:442-447
10. Gottlieb AB, Lebwohl M, Shirin S, Sherr A et al (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43:595-604
11. Hammar H, Gu SQ, Johannesson A, Sundkvist KG et al (1984) Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor/cytotoxic T cells in epidermis during the evolution of the lesion. J Invest Dermatol 83:416-420
12. Harding S, Lipp P, Alexander DR (2002) A therapeutic CD4 monoclonal antibody inhibits TCR-zeta chain phosphorylation, zeta-associated protein of 70-kDa Tyr319 phosphorylation, and TCR internalization in primary human T cells. J Immunol 169:230-238
13. Kim YH, Duvic M, Knox SJ, Baadsgaard O (2004) Fully human anti-CD4 monoclonal antibody: phase II trial in cutaneous T-cell lymphoma (CTCL). J Invest Dermatol 122:A57 (abstract)
14. Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1-23
15. Marschner S, Hunig T, Cambier JC, Finkel TH (2002) Ligation of human CD4 interferes with antigen-induced activation of primary T cells. Immunol Lett 82:131-139
16. Mease PJ, Goffe BS, Metz J, VanderStoep A et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385-390
17. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM (1995) Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 146:580-588
18. + T cells induces psoriasis. Am J Pathol 155:145-158
19. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA (2000) Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 24:212-225
20. Nickoloff BJ (2000) Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Invest Dermatol Symp Proc 5:67-73
21. Nikaein A, Morris L, Phillips C, Soliman M et al (1993) Characterization of T-cell clones generated from skin of patients with psoriasis. J Am Acad Dermatol 28:551-557
22. Parnes JR (1989) Molecular biology and function of CD4 and CD8. Adv Immunol 44:265-311
23. Placek W, Haftek M, Thivolet J (1988) Sequence of changes in psoriatic epidermis. Immunocompetent cell redistribution precedes altered expression of keratinocyte differentiation markers. Acta Derm Venereol 68:369-377
24. Ramirez-Bosca A, Martinez-Ojeda L, Valcuende-Cavero F, Castells-Rodellas A (1988) A study of local immunity in psoriasis. Br J Dermatol 119:587-595
25. Rook AH, Heald P (1995) The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:997-1010
26. Schlaak JF, Buslau M, Jochum W, Hermann E et al (1994) T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145-149
27. Schon MP (1999) Animal models of psoriasis - what can we learn from them? J Invest Dermatol 112:405-410
28. Skov L, Kragballe K, Zachariae C, Obitz ER et al (2003) Hu-Max-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of Psoriasis vulgaris. Arch Dermatol 139:1433-1439
29. Strange P, Cooper KD, Hansen ER, Fisher G et al (1993) T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol 101:695-700
30. +CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174:164-173
31. Uyemura K, Yamamura M, Fivenson DF, Modlin RL et al (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701-705
32. Villadsen LS, Schuurman J, Beurskens F, Dam TN et al (2003) Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 112:1571-1580
33. White SH, Newcomer VD, Mickey MR, Terasaki PI (1972) Disturbance of HL-A antigen frequency in Psoriasis. N Engl J Med 287:740-743